Teleflex Incorporated (NYSE:TFX) insider Thomas E. Powell sold 5,200 shares of Teleflex stock in a transaction on Friday, October 12th. The shares were sold at an average price of $246.84, for a total value of $1,283,568.00. Following the completion of the sale, the insider now owns 15,351 shares in the company, valued at approximately $3,789,240.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
TFX stock opened at $249.13 on Tuesday. The company has a current ratio of 2.21, a quick ratio of 1.45 and a debt-to-equity ratio of 0.88. The firm has a market capitalization of $12.19 billion, a P/E ratio of 29.66, a PEG ratio of 1.87 and a beta of 1.12. Teleflex Incorporated has a 12-month low of $227.52 and a 12-month high of $288.78.
Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, August 2nd. The medical technology company reported $2.47 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.41 by $0.06. The firm had revenue of $609.87 million for the quarter, compared to the consensus estimate of $615.97 million. Teleflex had a return on equity of 17.32% and a net margin of 3.78%. The company’s quarterly revenue was up 15.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.04 EPS. On average, research analysts expect that Teleflex Incorporated will post 9.82 EPS for the current year.
TFX has been the topic of a number of research analyst reports. ValuEngine downgraded Teleflex from a “buy” rating to a “hold” rating in a research report on Friday, August 3rd. Needham & Company LLC reduced their target price on Teleflex from $298.00 to $279.00 and set a “buy” rating on the stock in a research report on Friday, August 3rd. Morgan Stanley reduced their target price on Teleflex from $310.00 to $295.00 and set an “overweight” rating on the stock in a research report on Friday, August 3rd. TheStreet downgraded Teleflex from a “b” rating to a “c+” rating in a research report on Friday, August 3rd. Finally, Barclays assumed coverage on Teleflex in a research report on Monday. They issued an “equal weight” rating on the stock. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Teleflex presently has a consensus rating of “Buy” and a consensus target price of $289.25.
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Recommended Story: Diversification in Your Portfolio
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.